Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research DOI Creative Commons
Mingxia Liu, Wen Ma,

Yi He

et al.

Molecules, Journal Year: 2023, Volume and Issue: 28(21), P. 7430 - 7430

Published: Nov. 4, 2023

Major depressive disorder (MDD) is a serious mental illness with heavy social burden, but its underlying molecular mechanisms remain unclear. Mass spectrometry (MS)-based metabolomics providing new insights into the heterogeneous pathophysiology, diagnosis, treatment, and prognosis of MDD by revealing multi-parametric biomarker signatures at metabolite level. In this comprehensive review, recent developments MS-based in research are summarized from perspective analytical platforms (liquid chromatography-MS, gas supercritical fluid etc.), strategies (untargeted, targeted, pseudotargeted metabolomics), key changes (monoamine neurotransmitters, amino acids, lipids, antidepressant treatments (both western traditional Chinese medicines). Depression sub-phenotypes, comorbid depression, multi-omics approaches also highlighted to stimulate further advances field research.

Language: Английский

(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders DOI Open Access
Hana Shafique,

Julie Demers,

Julia Biesiada

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6804 - 6804

Published: June 20, 2024

NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative epilepsy, traumatic brain injury, substance abuse disorder (SUD), major depressive (MDD). (S)-ketamine was the first of a novel class antidepressants, rapid-acting to be approved medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development treatment-resistant depression (TRD). compound has demonstrated efficacy multiple animal models. Two clinical studies disclosed TRD bipolar depression. A study by drug sponsor recently failed reach priori endpoints but post hoc analysis revealed efficacy. value supported experimental data humans rodents, showing that it less sedating, does not produce marked psychotomimetic or dissociative effects, than (S)-ketamine, produces models range disorders. mechanisms action antidepressant effects are hypothesized due antagonism and/or non-NMDA mechanisms. We suggest further experimentation with will create improved medicines some disorders underserved current medications.

Language: Английский

Citations

9
Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review DOI
Aleksander Kwaśny, Julia Kwaśna, Alina Wilkowska

et al.

European Neuropsychopharmacology, Journal Year: 2024, Volume and Issue: 86, P. 20 - 34

Published: June 24, 2024

Language: Английский

Citations

6
Comparing presumptive with direct-to-definitive drug testing in oral fluid vs. urine for a U.S. national sample of individuals misusing drugs DOI Creative Commons
Stephen Magura, Miranda J. Lee-Easton,

Ruqayyah Abu-Obaid

et al.

Drug and Alcohol Dependence, Journal Year: 2023, Volume and Issue: 250, P. 110894 - 110894

Published: July 15, 2023

Language: Английский

Citations

6
Recent Progress in Mass Spectrometry-Based Metabolomics in Major Depressive Disorder Research DOI Creative Commons
Mingxia Liu, Wen Ma,

Yi He

et al.

Molecules, Journal Year: 2023, Volume and Issue: 28(21), P. 7430 - 7430

Published: Nov. 4, 2023

Major depressive disorder (MDD) is a serious mental illness with heavy social burden, but its underlying molecular mechanisms remain unclear. Mass spectrometry (MS)-based metabolomics providing new insights into the heterogeneous pathophysiology, diagnosis, treatment, and prognosis of MDD by revealing multi-parametric biomarker signatures at metabolite level. In this comprehensive review, recent developments MS-based in research are summarized from perspective analytical platforms (liquid chromatography-MS, gas supercritical fluid etc.), strategies (untargeted, targeted, pseudotargeted metabolomics), key changes (monoamine neurotransmitters, amino acids, lipids, antidepressant treatments (both western traditional Chinese medicines). Depression sub-phenotypes, comorbid depression, multi-omics approaches also highlighted to stimulate further advances field research.

Language: Английский

Citations

5